Through the agreement, BMS will supply its best-selling cancer drug Opdivo for Bavarian Nordic to use in a clinical trial.
The study, expected to include around 160 patients, will examine the efficacy of combining its drug CV301 with Opdivo in patients with previously untreated non-small cell lung cancer.
Bavarian Nordic will maintain all commercial rights for CV301.
The study is expected to start later this year.
More articles on the drug market:
Secretive board at Express Scripts determines drug exclusions
Aurobindo Pharma to open vaccine manufacturing facility
Lethal drug poses new threat to the opioid epidemic
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
